181 related articles for article (PubMed ID: 24238267)
21. Depo Provera. Position paper on clinical use, effectiveness and side effects.
Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
[TBL] [Abstract][Full Text] [Related]
22. Depo-Provera highly effective as injectable contraceptive.
Denniston GC
Contracept Technol Update; 1985 Dec; 6(12):167-8. PubMed ID: 12280301
[TBL] [Abstract][Full Text] [Related]
23. Preventing repeat teen pregnancy: postpartum depot medroxyprogesterone acetate, oral contraceptive pills, or the patch?
Thurman AR; Hammond N; Brown HE; Roddy ME
J Pediatr Adolesc Gynecol; 2007 Apr; 20(2):61-5. PubMed ID: 17418388
[TBL] [Abstract][Full Text] [Related]
24. Hysteroscopic sterilization in patients with a Mirena intrauterine device: transition from extended interval to permanent contraception.
Tatalovich JM; Anderson TL
J Minim Invasive Gynecol; 2010; 17(2):228-31. PubMed ID: 20226413
[TBL] [Abstract][Full Text] [Related]
25. [The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years)].
Imperato F; Perniola G; Mossa B; Marziani R; Perniola F; Stragapede B; Napolitano C
Minerva Ginecol; 2002 Jun; 54(3):271-8. PubMed ID: 12063443
[TBL] [Abstract][Full Text] [Related]
26. Depo-Provera -- proving its innocence.
Choudhury IR
Indian Med Trib; 1994 Jul; 2(11):5. PubMed ID: 12179187
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the effects of the levonorgestrel-releasing intrauterine system (Mirena) and depot-medroxyprogesterone acetate (Depo-Provera) on subendometrial microvascularisation and uterine artery blood flow.
Dane B; Akca A; Dane C; Evcimen S; Cetin A
Eur J Contracept Reprod Health Care; 2009 Jun; 14(3):240-4. PubMed ID: 19565422
[TBL] [Abstract][Full Text] [Related]
28. Characteristics of contraceptive acceptors in Luanda, Angola.
Carvalho A; Laudari C; Marini M; Faundes A
Afr J Fertil Sexual Reprod Heal; 1996 Dec; 1(2):109-14. PubMed ID: 12321195
[TBL] [Abstract][Full Text] [Related]
29. Depo-Provera use in Sri Lanka: acceptor characteristics, continuation and side effects.
Basnayake S; Thapa S
Adv Contracept Deliv Syst; 1986 Oct; 2(4):307-21. PubMed ID: 12341188
[TBL] [Abstract][Full Text] [Related]
30. Injectable contraception.
International Planned Parenthood Federation IPPF. International Medical Advisory Panel IMAP
IPPF Med Bull; 1980 Dec; 14(6):1-3. PubMed ID: 12310087
[TBL] [Abstract][Full Text] [Related]
31. The use of Depo-Provera in East London.
Savage W
Fertil Contracept; 1978 Jul; 2(3):41-7. PubMed ID: 12260723
[TBL] [Abstract][Full Text] [Related]
32. Teens and Depo-Provera: a good match?
Contracept Technol Update; 1995 Jul; 16(7):86-8. PubMed ID: 12346507
[TBL] [Abstract][Full Text] [Related]
33. Choosing a contraceptive. What's best for you?
Anthony J
Am Health; 1994 Apr; 13(3):68-71. PubMed ID: 12290558
[TBL] [Abstract][Full Text] [Related]
34. A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development.
Shaamash AH; Sayed GH; Hussien MM; Shaaban MM
Contraception; 2005 Nov; 72(5):346-51. PubMed ID: 16246660
[TBL] [Abstract][Full Text] [Related]
35. The use of depot medroxyprogesterone acetate (DMPA) injectable contraceptive in Enugu, Nigeria.
Hu E; Ikeako LC; Obiora-Okafor NC
Niger J Med; 2012; 21(3):266-71. PubMed ID: 23304918
[TBL] [Abstract][Full Text] [Related]
36. Depo-Provera Versus Norethisterone Acetate in Management of Endometrial Hyperplasia Without Atypia.
Nooh AM; Abdeldayem HM; Girbash EF; Arafa EM; Atwa K; Abdel-Raouf SM
Reprod Sci; 2016 Apr; 23(4):448-54. PubMed ID: 26718306
[TBL] [Abstract][Full Text] [Related]
37. Use of a long-acting injectable contraceptive in a postpartum family planning program.
Mcdaniel EB; Pardthaisong T
Asian J Med; 1973 Apr; 9(4):133-5. PubMed ID: 12262537
[TBL] [Abstract][Full Text] [Related]
38. Not FDA-approved, but experts recommend Depo-Provera.
Contracept Technol Update; 1992 Jan; 13(1):1-7. PubMed ID: 12343458
[TBL] [Abstract][Full Text] [Related]
39. Intrauterine contraception for adolescents aged 14-18 years: a multicenter randomized pilot study of levonorgestrel-releasing intrauterine system compared to the Copper T 380A.
Godfrey EM; Memmel LM; Neustadt A; Shah M; Nicosia A; Moorthie M; Gilliam M
Contraception; 2010 Feb; 81(2):123-7. PubMed ID: 20103449
[TBL] [Abstract][Full Text] [Related]
40. The contraceptive use of Depo-Provera in U.S. adolescents.
Pinkston Koenigs LM; Miller NH
J Adolesc Health; 1995 May; 16(5):347-9. PubMed ID: 7662682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
